By Editorial Staff
In the high-stakes world of medical research, the intersection of patient advocacy and scientific rigor is where breakthroughs are born. For Dr. Kelly Shanahan, M.D., the President of the organization, this intersection is not merely a professional obligation—it is a lived experience. In a recent dispatch, Dr. Shanahan provided a candid look at the grueling reality of life on the front lines of disease advocacy, while simultaneously sounding a clarion call for the funding necessary to sustain the 2026 research grant cycle.
As the organization faces an unprecedented volume of research proposals, the necessity for sustained financial support has never been more acute. This article explores the current state of the organization’s research initiatives, the logistical realities of the leadership, and the broader implications for the future of translational medicine.
The Landscape of Advocacy: A Personal Perspective
For Dr. Shanahan, the past two months have been defined by a blur of airport terminals and transcontinental flights. Her recent schedule—a grueling regimen of traveling over 1,100 miles each way to participate in a clinical trial—serves as a microcosm of the modern patient-advocate experience.
"I feel like all I do is unpack my suitcase, do laundry, and then put the clothes back in the suitcase," Dr. Shanahan remarked, highlighting the persistent cycle of travel required to stay at the vanguard of clinical research. Whether it is attending high-level medical conferences, participating in pivotal advocacy events, or managing the delicate balance of personal life, the life of a leader in medical non-profits is one of unrelenting motion.
This personal narrative is not incidental; it underscores the urgency of the mission. When the leader of an organization is actively engaged in the clinical trial process, the motivation behind the fundraising goals shifts from abstract corporate targets to tangible, life-saving necessities.
Chronology: The 2026 Grant Cycle and Operational Milestones
The administrative engine of the organization is currently operating at maximum capacity as it navigates the 2026 grant cycle. The timeline of this cycle reflects both the growth of the organization and the escalating complexity of the research it supports.
- Early 2025 (Initial Outreach): The organization began soliciting Letters of Intent (LoIs) from researchers globally. The focus for this cycle was specifically on projects that could demonstrate a clear path from laboratory bench to bedside.
- Mid-2025 (Volume Assessment): The organization experienced a record-breaking surge in submissions. This influx of interest suggests that despite economic fluctuations, the scientific community remains deeply committed to pursuing answers in this specific therapeutic area.
- Current Phase (Review and Evaluation): Currently, the organization is in the critical stage of vetting these submissions. This process involves a dual-track review system, requiring both the scrutiny of seasoned scientific experts and the vital, lived-experience perspectives of patient advocates.
- Q4 2025 (Funding Finalization): The organization is currently finalizing its fundraising push to meet the $3.75 million goal, which will provide the necessary liquidity to award the grants in the upcoming year.
Supporting Data: The Anatomy of a Record-Breaking Year
The data emerging from the 2026 LoI process is telling. The sheer volume of applications is, in itself, a testament to the scientific community’s dedication to solving the medical challenges at hand.
The Translational Award Mechanism
Of the total volume of applications received, a staggering 75% are directed toward the $450,000 translational award mechanism. This is a significant indicator of the current trends in research. Translational research—which focuses on turning discoveries made in the laboratory into clinical applications—is expensive, high-risk, and essential.
- Total Grant Goal: $3.75 million.
- Primary Focus: Translational Research (75% of submissions).
- Review Methodology: Hybrid model (Scientific experts + Patient advocate input).
The concentration of interest in translational awards reveals that the scientific community is moving away from purely theoretical study and toward projects with direct, near-term clinical impact. However, this shift places a heavy burden on the organization’s resources. A $450,000 grant per project is a substantial investment, and with a high number of qualified applicants, the funding gap remains a persistent challenge.
Official Responses and Strategic Pivot
In response to the economic uncertainties affecting the global landscape, the organization’s leadership has adopted a strategy of "pragmatic ambition."
"We have had lofty goals in the past for how much money we want to raise for research," Dr. Shanahan noted. "But with the uncertainty in the world, we are being a little bit more realistic."
By recalibrating the annual fundraising target to $3.75 million, the organization is attempting to balance the desire to fund as much high-quality science as possible with the fiscal responsibility required to ensure the organization’s long-term viability. This strategic pivot is intended to ensure that the organization can honor its commitments to researchers without overextending its reserves in a volatile economic climate.
The Power of Micro-Donations
The leadership is emphasizing that the path to $3.75 million is not solely paved by high-net-worth donors. Instead, they are appealing to the collective power of the community. Dr. Shanahan’s suggestion—that individuals consider giving up a "fancy coffee" to donate—is a recognition of the democratization of philanthropy. In the face of a multimillion-dollar goal, the aggregate impact of small, consistent donations from thousands of supporters becomes a significant force.
Implications: The Future of Translational Medicine
The implications of the current funding cycle are profound. If the organization meets its $3.75 million target, it will be able to fund a robust portfolio of research that could, in theory, alter the standard of care for patients within the next decade.
The Necessity of the Patient Voice
One of the most important aspects of the current review cycle is the inclusion of patient advocate reviewers. By integrating the patient perspective into the grant-awarding process, the organization ensures that the research being funded is not only scientifically sound but also relevant to the actual needs and quality-of-life concerns of the patient population. This creates a feedback loop where science is constantly being refined by the reality of the illness.
Economic and Scientific Resilience
The organization is proving that it can withstand both internal and external pressures. The resilience required to manage record numbers of applications while simultaneously navigating the personal struggles of health-related travel is a hallmark of the organization’s culture.
However, the ultimate success of the 2026 cycle remains tethered to public participation. The "uncertainty in the world" mentioned by Dr. Shanahan is a reality that affects all non-profits, but medical research organizations face a unique pressure: the work cannot be paused. Diseases do not wait for economic recoveries, and researchers cannot sustain their labs on hope alone.
Conclusion: A Call to Action
The dispatch from Dr. Kelly Shanahan serves as both a report card and a rallying cry. It highlights the exhausting, essential, and ultimately hopeful nature of medical advocacy. As the organization moves into the final stages of the 2026 grant review, the community is reminded that progress is not an accident—it is a product of deliberate, collective effort.
Whether it is the scientist working in a lab, the patient participating in a trial, or the donor contributing to the research fund, every participant plays a critical role. The $3.75 million goal is more than a number; it is the fuel for the next generation of breakthroughs. As the organization prepares to announce the recipients of the 2026 grants, the message is clear: the work is hard, the stakes are high, and the progress depends entirely on the willingness of the community to invest in a healthier future.
The suitcases will eventually be unpacked, and the laundry will be finished, but the impact of the research funded today will resonate for years to come.
About the Author
